CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. (NASDAQ:MRNA) have entered into a strategic partnership that will harness Moderna’s…
Boehringer Ingelheim’s SPEVIGO wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023…
FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA)…
GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK GSK plc today announced the launch of a £6m, 10-year STEM equity…
Moderna Named a Top Employer by Science for Ninth Consecutive Year Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry…
Immunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, proudly announces…
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech Johnson & Johnson (NYSE: JNJ) (the Company) announced today that Ashley McEvoy,…
Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer Positive results from the primary analysis of the DUO-E…
Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) The approval by the National Medical Products Administration (NMPA) in China was based on results…
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents Pfizer Inc. (NYSE: PFE) announced today that the…
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting…
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023 Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023 following the presentation…